Friday, October 30, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· October 16, 2026

Palantir Technologies declines 7% amid broader tech selloff

View original at seekingalpha.com
Palantir Technologies declines 7% amid broader tech selloff [Palantir Technologies headquarters campus exterior view in Silicon Valley…
Opening lines of the source · Seeking Alpha · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Remains constructive on Palantir. Emphasizes customer expansion and net dollar retention as central to the bull case, while acknowledging that the elevated forward valuation makes continued execution essential.

    60% confidence
  • Upgraded Palantir to Buy after concluding that customer-built AI applications can remain complementary to Palantir's platforms rather than displace its core offering.

    60% confidence
  • Strongly bullish on Palantir. Points to government awards, Maven deployments, larger customer deals and operating leverage as evidence that consensus estimates underestimate its earnings potential.

    60% confidence
  • Reiterates a bullish rating on Palantir, citing the Goldman Sachs upgrade, AI-platform adoption, commercial growth, profitability and technical momentum. Flags valuation, customer concentration and share dilution as risks.

    60% confidence
  • Bullish growth-investor case centered on Palantir's secure private AI environments, revenue growth, operating leverage and free cash flow, while cautioning that the valuation may already reflect much of the expected enterprise-AI opportunity.

    60% confidence
  • Bullish on Palantir. Highlights customer expansion, net dollar retention, remaining deal value and expected earnings growth. Names high valuation, dilution, customer concentration and competition as the primary risks.

    60% confidence
  • Bearish on Palantir. Argues its current valuation requires capturing an exceptionally large share of its addressable market and that it faces competitive pressure from large technology companies delivering related functionality through existing cloud products.

    60% confidence
  • Upgraded Palantir from Neutral to Buy, citing recent underperformance and the prospect of another growth phase driven by sovereign AI, customized applications, and Palantir's forward-deployed engineering model.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com